CorEvitas Multiple Sclerosis (MS) Registry

NCT03291756 | Enrolling By Invitation

• 1 other identifier: CorEvitas-MS-700
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for MS in a cohort of patients cared for by neurologists across North America. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (1)

• Number of patients with adverse events (AEs) or serious adverse events (SAEs).

  Targeted events include malignancy, anaphylaxis, cardiovascular disease, serious infection, autoimmune disease, MS Relapse, hepatic events, and general serious adverse events. An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

  Time Frame: A minimum of 10 years from last patient enrolled

Secondary Outcomes (8)

• Patient reported: Patient Clinical Global Impression (PCGI) Scale

  Time Frame: every 6 months for 10 years

• Disease burden: Relapse Information

  Time Frame: every 6 months for 10 years

• Percentage of patients with history of comorbidities

  Time Frame: at registry enrollment

• Physician reported: Nine-Hole Peg Test (9-HPT)

  Time Frame: every 6 months for 10 years

• Physician reported: Symbol Digit Modalities Test (SMDT)

  Time Frame: every 6 months for 10 years

Study Arms (1)

Multiple Sclerosis

Multiple Sclerosis Pts presenting to enrolling sites across the US are invited to enroll if eligible

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients are enrolled in the Multiple Sclerosis (MS) Registry during regularly -scheduled office visits. Selected neurologists are invited to participate as investigators in the Registry.

You may qualify if:

• Has a diagnosis of MS at the time of enrollment.
• Age 18 years or older at the time of enrollment.
• Willing to provide Personal Information.
• Initiating (prescribed or starting) an Eligible Medication for the treatment of MS at the enrollment visit.

You may not qualify if:

• \) Is participating or planning to participate in a double-blind randomized trial for an MS drug. Note: Concurrent participation in another observational registry or open-label Phase 3b/4 trial is allowed.

Sponsors & Collaborators

• CorEvitas: lead

Study Sites (1)

CorEvitas, LLC

Waltham, Massachusetts, 02451, United States

Location

Related Links

• CorEvitas home page

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: NETWORK
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: August 24, 2017
• First Posted: September 25, 2017
• Study Start: August 10, 2017
• Primary Completion (Estimated): December 1, 2100
• Study Completion (Estimated): December 1, 2100
• Last Updated: February 9, 2026

Record last verified: 2026-01

Locations

US (1)